Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers

Fig. 2

Association between EPH7A mutation and clinical outcomes in the discovery cohort. a Associations between EPH gene mutation and clinical responses (ORR and DCB). Both dashed lines indicated B-H adjusted P = 0.05 regarding DCB and ORR, respectively (two-tailed Fisher’s exact test). b Histogram depicting proportions of ORR in EPHA7-MUT and EPHA7-WT patients (two-tailed Fisher’s exact test). c Histogram depicting proportions of DCB in EPHA7-MUT and EPHA7-WT patients (two-tailed Fisher’s exact test). d The Kaplan-Meier survival analysis comparing PFS between EPHA7-MUT and EPHA7-WT patients in the discovery cohort (n = 349). There were 349 patients with available PFS data for PFS analysis. Missing PFS data consisted of 37 patients from Hugo et al. cohort. e The Kaplan-Meier survival analysis comparing OS between EPHA7-MUT and EPHA7-WT patients in the discovery cohort. There were 311 patients with available OS data for OS analysis. Missing OS data consisted of 75 patients from Hellman et al. cohort. HR and adjusted P in d and e were calculated by the Cox proportional hazards regression analysis. Available confounding factors were adjusted: age, sex, cancer type, drug class, and TMB level. ORR, objective response rate; SD, stable disease; PD, progressive disease; CR, complete response; PR, partial response; DCB, durable clinical benefit; NCB, no clinical benefits; PFS, progression-free survival; OS, overall survival; B-H: Benjamini-Hochberg procedure

Back to article page